Blood marker may forecast deadly pancreatic surgery complications

NCT ID NCT07144917

Recruiting now Knowledge-focused Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a blood marker called mHLA-DR can help doctors predict severe complications after pancreatic surgery. About 100 people having this surgery will be followed. The goal is to find an early warning sign for problems like infection or pancreatic leaks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA (MPDAC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic ductal adenocarcinoma Pancreatic Fistula pancreatic neoplasm Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC DUCTAL ADENOCARCINOMA (MPDAC) PANCREATIC FISTULA PANCREATIC HEAD TUMOUR

Contacts and locations

Locations

Aurélien DUPRE
NOT_YET_RECRUITING

Lyon, 69008, France
Jean-Christophe LIFANTE
NOT_YET_RECRUITING

Pierre-Bénite, 69495, France
Julie PERINEL
NOT_YET_RECRUITING

Lyon, 69003, France
Xavier MULLER
RECRUITING

Lyon, 69004, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.